Here, therefore, we present two randomized, double‐blind, placebo‐controlled, parallel‐group studies designed to assess the safety and metabolic effects of eptinezumab treatment in non‐migraine overweight/obese patients (study 1) and to assess safety and changes in insulin sensitivity and daily insulin requirements in patients with type 1 diabetes (T1D; study 2). This evidence concerns the gene INS and type 1 diabetes mellitus.